ESMO Open最新文献

{"title":"71P When neighbors play a role: The importance of interacting proteins in the tumorigenic effect of cancer driver genes","authors":"M. Carrolo , M. Vital , J. Miranda , A. Quintela , F. Pinto","doi":"10.1016/j.esmoop.2024.103815","DOIUrl":"10.1016/j.esmoop.2024.103815","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology","authors":"C. Macarro , P. Cresta Morgado , S. Simonetti , D. Navarro , H. Alatoom , C. Zatse , D. Olmos , P.G. Nuciforo , A. Vivancos , R. Olivera-Salguero , T. Pascual , J. Carles Galceran , E. Castro , J. Mateo , R. Perez Lopez","doi":"10.1016/j.esmoop.2024.103748","DOIUrl":"10.1016/j.esmoop.2024.103748","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"6P Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis","authors":"D. Arruda Navarro Albuquerque , M. Trotta Vianna , A. Vasiliu , E.H. Cunha Neves Filho","doi":"10.1016/j.esmoop.2024.103752","DOIUrl":"10.1016/j.esmoop.2024.103752","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study","authors":"Á. Guerrero-Zotano ,&nbsp;J.M. Pérez-García ,&nbsp;M. Ruiz-Borrego ,&nbsp;B. Bermejo ,&nbsp;M. Gil-Gil ,&nbsp;J. de la Haba ,&nbsp;E. Alba Conejo ,&nbsp;V. Quiroga ,&nbsp;V. Carañana ,&nbsp;A. Urruticoechea ,&nbsp;S. Morales ,&nbsp;M. Bellet ,&nbsp;A. Antón ,&nbsp;M. Fernández-Abad ,&nbsp;P. Sánchez-Rovira ,&nbsp;L. Calabuig ,&nbsp;J. Pérez-Escuredo ,&nbsp;M. Sampayo-Cordero ,&nbsp;J. Cortés ,&nbsp;A. Llombart-Cussac","doi":"10.1016/j.esmoop.2024.103733","DOIUrl":"10.1016/j.esmoop.2024.103733","url":null,"abstract":"<div><h3>Background</h3><div>The effect of the addition of cyclin-dependent kinases 4 and 6 inhibitors to endocrine therapy in terms of molecular downstaging remains undetermined. Switching from a high-risk to a low risk Recurrence Score (RS) group could provide useful information to identify patients who might not require chemotherapy. The purpose of this study was to assess the biological and clinical activity of letrozole plus palbociclib as neoadjuvant treatment for patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with an initial Oncotype DX RS ≥18.</div></div><div><h3>Patients and methods</h3><div>Participants were women aged ≥18 years with HR-positive/HER2-negative, Ki67 ≥ 20%, stage II-IIIB early breast cancer with a baseline RS ≥18. Eligible patients with a pretreatment RS 18-25 (cohort A) and 26-100 (cohort B) received six 28-day cycles of letrozole (2.5 mg per day; plus goserelin if pre- or perimenopausal) plus palbociclib (125 mg per day; 3/1 schedule) before surgery. The primary endpoint for both cohorts was the proportion of patients who achieved an RS ≤25 at surgery or a pathological complete response (pCR).</div></div><div><h3>Results</h3><div>A total of 67 patients were enrolled, among which 65 were assessable for the primary endpoint (32 patients in cohort A and 33 in cohort B). At surgery, 22 (68.8%) patients in cohort A and 18 (54.5%) patients in cohort B had an RS ≤25 or a pCR [only 1 (3.0%) patient in cohort B], meeting the primary endpoint in cohort B (<em>P</em> &lt; 0.01), but not in cohort A (<em>P</em> = 0.98). No new safety signals were identified.</div></div><div><h3>Conclusions</h3><div>The efficacy of neoadjuvant treatment with letrozole plus palbociclib does not seem to depend on pretreatment RS for patients with RS ≥18. However, around half of patients with HR-positive/HER2-negative early breast cancer with an RS 26-100 at baseline achieved molecular downstaging with this regimen.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study","authors":"F. Tosi ,&nbsp;L. Salvatore ,&nbsp;E. Tamburini ,&nbsp;S. Artale ,&nbsp;S. Lonardi ,&nbsp;S. Marchetti ,&nbsp;A. Pastorino ,&nbsp;F. Pietrantonio ,&nbsp;A. Puccini ,&nbsp;F.L. Rojas-Llimpe ,&nbsp;B. Vincenzi ,&nbsp;S. Mariano ,&nbsp;F. Negri ,&nbsp;K. Bencardino ,&nbsp;C. Pinto ,&nbsp;C. Aschele ,&nbsp;S. Siena","doi":"10.1016/j.esmoop.2024.103929","DOIUrl":"10.1016/j.esmoop.2024.103929","url":null,"abstract":"<div><h3>Background</h3><div>Sustained clinical complete remissions were reported in all of 23 mismatch repair deficient/microsatellite instable (dMMR/MSI) locally advanced rectal cancer (LARC) patients treated with dostarlimab alone in a recent phase II study. These results led to off-label use of dostarlimab or other immune checkpoint inhibitors (ICIs) in dMMR/MSI-LARC even before regulatory approval. The present study [STAR(t)-IT-REDUCE] describes the outcome of dMMR/MSI-LARC patients treated with ICI in Italy.</div></div><div><h3>Materials and methods</h3><div>Investigator-initiated, observational, retrospective-cohort, multicentric study of ICI treatment in dMMR/MSI-LARC. Patients were eligible if treated with ≥1 ICI dose from July 2022 to December 2023 (date of approval of dostarlimab for this indication in Italy).</div></div><div><h3>Results</h3><div>Seventeen dMMR/MSI-LARC patients (13 of 17 treatment-naïve) were eligible. Fourteen patients completed 6 months of treatment, two discontinued after four doses and one after five doses because of immune-related pneumonia, social constraints, or non-oncological bowel obstruction, respectively. Overall, 16 of 17 assessable patients [94.1%; 95% confidence interval (CI) 69.24% to 99.69%, ‘ITT analysis’] achieved complete clinical response (cCR). Ten of 11 treatment-naïve patients completing 6 months of treatment had cCR (90.9%; 95% CI 57.12% to 99.52%, ‘per-protocol analysis’). One patient with near-CR underwent rectal surgery and minimal residual intramucosal tumor was found. With a median follow-up of 9.5 months, no local relapse occurred. One patient developed unconfirmed lung metastases. Two grade 3 and no grade 4 adverse events were reported.</div></div><div><h3>Conclusion</h3><div>The present STAR(t)-IT-REDUCE study documents the immunoablative and curative activity of ICI monotherapy in dMMR/MSI-LARC. Toxicity and compliance issues inherent to real-world practice are limited and do not affect achievement of initial complete tumor response but may limit response duration.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"86P Functional impact of miR-205-5p on cervical cancer cell behavior and chemotherapy response","authors":"R.L. Causin ,&nbsp;A.J.A. de Freitas ,&nbsp;A.V.H. Lengert ,&nbsp;I.N.F. Gomes ,&nbsp;M.N. Rosa ,&nbsp;R.D. Reis ,&nbsp;R.M. Reis ,&nbsp;M.M.C. Marques","doi":"10.1016/j.esmoop.2024.103827","DOIUrl":"10.1016/j.esmoop.2024.103827","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"88P Impact of poly(ADP-ribose) polymerase (PARP) mutations on interaction with PARP inhibitors (iPARPs)","authors":"J.F. Diaz Acosta ,&nbsp;L.D. Gutierrez ,&nbsp;G. Ardila Patiño ,&nbsp;J. Carvajal Veloza ,&nbsp;A.T. Palacios ,&nbsp;C.A. Maya","doi":"10.1016/j.esmoop.2024.103829","DOIUrl":"10.1016/j.esmoop.2024.103829","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"52P RAS mutation status and mutation type as potential predictive biomarkers for thrombosis in metastatic colorectal cancer: A tertiary center 12-year cohort analysis","authors":"J. Leão Mendes,&nbsp;R.Q. Ferreira,&nbsp;R. Escaleira,&nbsp;F. Verdasca,&nbsp;M. Seladas,&nbsp;J. Gramaça,&nbsp;S. Duarte Oliveira","doi":"10.1016/j.esmoop.2024.103797","DOIUrl":"10.1016/j.esmoop.2024.103797","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"67P Multi-institutional evaluation of interrater agreement of biomarker-drug pair rankings based on the ESMO scale for clinical actionability of molecular targets (ESCAT) and sources of discordance","authors":"A. Lebedeva ,&nbsp;A. Taraskina ,&nbsp;E. Belova ,&nbsp;A. Kavun ,&nbsp;M. Bartoletti ,&nbsp;I. Bieche ,&nbsp;G. Curigliano ,&nbsp;C. Dupain ,&nbsp;M. Kamal ,&nbsp;E. Ignatova ,&nbsp;C. Luchini ,&nbsp;S. Poyarkov ,&nbsp;A. Rios-Hoyo ,&nbsp;C. Le Tourneau ,&nbsp;E. Veselovsky ,&nbsp;V. Mileyko ,&nbsp;M. Ivanov","doi":"10.1016/j.esmoop.2024.103811","DOIUrl":"10.1016/j.esmoop.2024.103811","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"55P Impact of IHC/PCR discordance on immunotherapy (ICI) response in colorectal cancer (CRC) patients and prospects of liquid biopsy (LB) to replace conventional methods: Survival analysis of BLOOMSI trial","authors":"A. Lebedeva ,&nbsp;O.A. Kuznetsova ,&nbsp;T. Grigoreva ,&nbsp;A. Taraskina ,&nbsp;D.A. Kravchuk ,&nbsp;E. Belova ,&nbsp;A. Kavun ,&nbsp;E. Ignatova ,&nbsp;E. Veselovsky ,&nbsp;L. Belyaeva ,&nbsp;V. Nikulin ,&nbsp;A. Sergeeva ,&nbsp;S. Aliyarova ,&nbsp;V. Mileyko ,&nbsp;A. Tryakin ,&nbsp;M. Fedyanin ,&nbsp;M. Ivanov","doi":"10.1016/j.esmoop.2024.103800","DOIUrl":"10.1016/j.esmoop.2024.103800","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}